N/A N=42 Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)
Vancomycin Resistance Enterococcus Faecium
Primary: Number of Participants With Adverse Drug Reactions. — 10; 3; 3; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=9 A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization
Antibiotic Resistant Strain
Primary: Percentage of Participants With VRE Decolonization — 1; 1 Participants
Phase 1 N=4 Vancomycin Pharmacokinetics in Patients on Peritoneal Dialysis
Peritoneal Dialysis-associated Peritonitis
Primary: Maximum Total Plasma Concentration (Cmax) — 28.7 mg/L
N/A N=99 Loading Vancomycin Doses in the Emergency Department
Infectious Disease
Primary: Percentage of Participants First Achieving Therapeutic Levels at 36 Hours — 20; 18 percentage of participants
Phase 2 N=9 Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients
Clostridium Difficile Infection · Hematologic Diseases · Bone Marrow Transplant
Primary: Changes in Clostridium Difficile Bacterial Loads in the Stool — 62102500.00; 40000000.00; 7752750.00; 185000.00 CFUs
Phase 2 N=29 Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)
Cystic Fibrosis
Primary: Number of Patients MRSA Free by Induced Sputum Respiratory Tract Culture — 2; 3 Participants
Phase 3 N=75 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
Urinary Tract Infection Complicated · Acute Pyelonephritis · Hospital Acquired Bacterial Pneumonia
Primary: Proportion of Subjects in the Microbiological Carbapenem-resistant Enterobacteriaceae Modified Intent-to-Treat (mCRE-MITT) Population With a Response of Overall Success…
Phase 4 N=51 Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics
Clostridium Difficile Infection · Prophylaxis · Vancomycin
Primary: Clostridium Difficile Infection Occurrence — 2; 0 Participants
Phase 2 N=15 The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome
End Stage Renal Disease
Primary: Change in Plasma Concentration Measure of Indoxyl Sulphate (IS) — -25.31; 9.71 µM/ml
Phase 4 N=1,225 Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
Methicillin Resistant Staphylococcus Aureus (MRSA)
Primary: Clinical Outcome in Participants With Baseline Methicillin Resistant Staphylococcus Aureus (MRSA) at End of Study (EOS) for PP Population — 95; 81; 70; 93 Participants…
Phase 3 N=761 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Bacterial Pneumonia
Primary: Clinical Response — 214; 221; 46; 68 participants
Phase 2 N=79 Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
Recurrent Clostridium Difficile Infection · Clostridium Difficile Infection · CDI
Primary: Recurrent Clostridium Difficile Infection (CDI) — 17; 24 Participants — p=0.22
Phase 3 N=1,036 Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
Post Operative Surgical Site Infection
Primary: Number of Clinically Significant Deep Surgical Site Infection (SSI) — 29; 48; 1; 1 surgical site infections
N/A N=188 Evaluation of Patients With Methicillin-Resistant Staphylococcus Aureus Hospital-Acquired Pneumonia Treated With Linezolid or Vancomycin
Methicillin-Resistant Staphylococcus Aureus (MRSA) · Hospital-Acquired Pneumonia
Primary: Percentage of Participants With Clinical Success — 85; 69 percentage of participants — p=0.009
Phase 3 N=757 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
Bacterial Pneumonia
Primary: Clinical Response — 227; 228; 53; 52 participants
Phase 1 N=1 FMT for Multidrug Resistant Organism Reversal
Infection With Multi-drug Resistant Organisms
Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants
Phase 3 N=22 Regional Prophylactic Vancomycin in Revision Total Knee Replacement
Arthropathy of Knee Joint
Primary: Mean Concentration of Vancomycin in Subcutaneous Fat — 94.1; 3.2; 88.3; 5.0 µg/g — p=<0.0001
N/A N=181 Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis
MRSA Infections
Primary: Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections. — 2; 0; 4 participants
Phase 3 N=939 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Staphylococcal Skin Infection
Primary: Clinical Response — 358; 364; 59; 57 patients
Phase 3 N=862 Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus Aureus
Staphylococcal Skin Infection
Primary: Clinical Response — 323; 321; 52; 58 participants
N/A N=210 Effect of Bed Bathing Methods on VRE Colonization in ICU Patients
Vancomycin-Resistant Enterococcus
Primary: Vancomycin-Resistant Enterococcus (VRE) Colonization — 0; 0; 30; 33 participants with VRE colonization — p=0.671
Phase 3 N=188 AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
MRSA · Cystic Fibrosis
Primary: Absolute Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Percent Predicted — 2.39; 1.18; 1.52; 0.13 Percent predicted — p=0.325
N/A N=4 Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections
Skin and Soft Tissue Infections
Primary: Clinical Efficacy — 2; 0 participants
Phase 4 N=674 Screening to Prophylax Against Clostridium Difficile Infection -
Clostridium Difficile Infection
Primary: The Incidence of CDI in Inpatients Receiving Vancomycin Prophylaxis vs. Placebo Who Are on High-risk Antibiotics and Are Colonized With Toxigenic C. Difficile. — 0; 0…
Phase 2 N=41 Catheter Related - Gram Positive Bloodstream Infections
Bloodstream Infection
Primary: Clinical Response Within 48 Hours — 28 Participants
Early Phase 1 N=25 The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery
Infection
Primary: Circulating Vancomycin Concentration — 15.6 µg/mL — p=<0.0001
Phase 4 N=144 A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Clostridium Difficile Infection (CDI)
Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195
N/A N=277 Swab Testing to Optimize Pneumonia Treatment With Empiric Vancomycin
Community-acquired Pneumonia
Primary: Vancomycin-free Hours Alive — 105.7; 109.7 Hours
Phase 1 N=25 Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics
Healthy · Cystic Fibrosis
Primary: Safety and Tolerability - Number of Participants With Treatment Emergent Adverse Events (TEAEs = Adverse Events That Started During or After the First Dose of Study…
Phase 3 N=303 Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Number of Subjects With Clinical Resolution of Bacterial Conjunctivitis — 71; 59 Participants — p=0.2219